Biohaven Pharma

220 articles with Biohaven Pharma

• Biohaven Receives Notice Of Allowance From U.S. Patent And Trademark Office On Patent Application For Glutamate Modulating Prodrugs

  7/13/2017

• Biohaven's BHV-5000 Receives Orphan Drug Designation From The FDA In Rett Syndrome

  7/6/2017

• Biohaven Added to Russell Microcap Index

  6/26/2017

• Biohaven Broadens Senior Leadership Team With Veteran Pharma Executives

  6/22/2017

• Biohaven Reports First Quarter 2017 Financial and Business Results

  6/16/2017

• Biohaven Completes Enrollment In Spinocerebellar Ataxia Clinical Trial With Trigriluzole

  5/30/2017

• Biohaven's Trigriluzole Receives Fast Track Designation From U.S. FDA

  5/15/2017

• Biohaven Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares

  5/15/2017

• Biohaven Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares

  5/12/2017

• Portage Biotech's Holding In Biohaven

  5/9/2017

• Biohaven Announces Pricing of its Initial Public Offering of Common Shares

  5/4/2017

• Biohaven Eyes $100 Million IPO to Bankroll Trials of Shelved AstraZeneca PLC, Bristol-Myers Squibb Drugs

  4/11/2017

• Biohaven Closes Second Tranche Of Private Placement And Appoints Two New Directors To Board

  3/8/2017

• Biohaven Closes Second Tranche Of Private Placement And Appoints Two New Directors To Board

  3/7/2017

• Biohaven Enrolls First Patient In Pivotal Trial Of BHV-4157 In Patients With Hereditary Spinocerebellar Ataxia

  12/22/2016

• Biohaven' BHV-0223 Is Granted Orphan Drug Designation In The Treatment Of Amyotrophic Lateral Sclerosis

  12/9/2016

• Biohaven Announces Orphan Drug Designation Request Granted For Bhv-0223 In The Treatment Of Amyotrophic Lateral Sclerosis ("Als")

  12/8/2016

• Biohaven Secures $80 Million In Oversubscribed Private Financing To Advance Phase 3 Clinical Trials

  11/1/2016

• Biohaven Licenses Rights From Rutgers University To Develop And Commercialize Glutamate Modulating Agents In Cancer Treatment

  10/3/2016

• Biohaven Commences Clinical Testing Of BHV-4157

  7/20/2016